ASCO GU Conference Coverage
Featured Articles
(CNN) Feb 16, 2019 - The way doctors typically approach kidney cancer treatment could be evolving. Two separate studies published Saturday in the New England Journal of Medicine showed that renal cell cancer patients had significantly better outcomes when their treatment combined the targeted therapy drug axitinib, or Inlyta, with an...
Read Article
(Reuters) Feb 16, 2019 - A combination of Merck & Co's immunotherapy Keytruda and Pfizer Inc's Inlyta helped patients with advanced kidney cancer live longer than those receiving and older Pfizer standalone therapy, according to data from a late-stage study presented on Saturday. Nearly 90 percent of patients who received the...
Read Article
Latest Articles
March 15, 2019
February 22, 2019
February 19, 2019
February 19, 2019
February 19, 2019
February 19, 2019
February 19, 2019
February 19, 2019
View More
News Commentary
Editor Image
22 Feb, 2019 | by Howard Sandler, MD, MS, FASTRO
The PACE (Prostate Advances in Comparative Evidence) trial with two...
View Comment
Editor Image
13 Feb, 2019 | by Tomasz M. Beer, MD
As contemporary hormonal agents are increasingly used earlier in prostate...
View Comment
View More
OBR Green
There are no ASCO GU Conference Coverage OBR Green articles.
OBR Blog
As the Genitourinary Cancers (GU) Symposium gets under way in San Francisco February 13-16 2019, at a pre-meeting... Read more
February 11, 2019